Network Meta-Analysis of Pharmacological Treatments for Fetal Growth Restriction

A 2026 network meta-analysis by Yanting Wei, published on figshare, evaluates the comparative effectiveness of drug treatments for fetal growth restriction. The 1.1 MB document contains results from a systematic review of clinical trials, including odds ratios for outcomes like intrauterine growth restriction and preeclampsia. The analysis follows PRISMA guidelines and includes evidence up to January 31, 2026.

Use Cases

• Comparing the efficacy of low-molecular-weight heparin versus low-dose aspirin based on reported odds ratios for IUGR.
• Assessing the impact of combined LMWH+LDA therapy on live birth rates based on the meta-analysis results.
• Evaluating the reduction in pregnancy complication risks (e.g., preeclampsia, preterm birth) associated with specific pharmacological treatments.
• Informing clinical guideline development for FGR management based on synthesized evidence from multiple trials.

Strengths

• Follows PRISMA guidelines for systematic review and network meta-analysis, indicating methodological rigor.
• Includes specific odds ratios and confidence intervals for key clinical outcomes like IUGR (OR=0.40) and live birth rate (OR=7.08).
• Search was updated through January 31, 2026, aiming to include recent evidence.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment for quantitative reuse.
• The dataset is a 1.1 MB DOCX file, which is a small document format not inherently structured for direct analysis.

Provenance

Source

figshare

Collection Method

Systematic literature review and network meta-analysis of clinical trials from databases including PubMed, Medline, Embase, and Cochrane.

Time Range

Evidence included up to January 31, 2026.

Freshness

Last updated 2026-04-15 05:22:36.

Geography

null